February 20, 2015 : Episode 1

Lenvatinib and Lenalidomide Approved, New Agent Promising in Myeloma, and More

Feb 20, 2015

Related Videos

Related Content

Patient Assessment Drives Treatment Advances in Multiple Myeloma

February 6th 2023

Expert and Patient Perspectives on Comprehensive Multiple Myeloma Treatment

December 22nd 2022

Docetaxel Added to Radiation Provides DFS, OS Benefit in Cisplatin-Ineligible HNSCC

February 2nd 2023

Mikhael and Cole Share Insights on Culturally Relevant Myeloma Care

October 27th 2022

Cilta-cel Meets PFS End Point in Relapsed/Lenalidomide-Refractory Multiple Myeloma

January 27th 2023

KRd Improves PFS as Maintenance Therapy in Transplant-Eligible Multiple Myeloma

January 25th 2023

Patient Assessment Drives Treatment Advances in Multiple Myeloma

February 6th 2023

Expert and Patient Perspectives on Comprehensive Multiple Myeloma Treatment

December 22nd 2022

Docetaxel Added to Radiation Provides DFS, OS Benefit in Cisplatin-Ineligible HNSCC

February 2nd 2023

Mikhael and Cole Share Insights on Culturally Relevant Myeloma Care

October 27th 2022

Cilta-cel Meets PFS End Point in Relapsed/Lenalidomide-Refractory Multiple Myeloma

January 27th 2023

KRd Improves PFS as Maintenance Therapy in Transplant-Eligible Multiple Myeloma

January 25th 2023

Patient Assessment Drives Treatment Advances in Multiple Myeloma

February 6th 2023

Expert and Patient Perspectives on Comprehensive Multiple Myeloma Treatment

December 22nd 2022

Docetaxel Added to Radiation Provides DFS, OS Benefit in Cisplatin-Ineligible HNSCC

February 2nd 2023

Mikhael and Cole Share Insights on Culturally Relevant Myeloma Care

October 27th 2022

Cilta-cel Meets PFS End Point in Relapsed/Lenalidomide-Refractory Multiple Myeloma

January 27th 2023

KRd Improves PFS as Maintenance Therapy in Transplant-Eligible Multiple Myeloma

January 25th 2023

Related Content

Patient Assessment Drives Treatment Advances in Multiple Myeloma

February 6th 2023

Expert and Patient Perspectives on Comprehensive Multiple Myeloma Treatment

December 22nd 2022

Docetaxel Added to Radiation Provides DFS, OS Benefit in Cisplatin-Ineligible HNSCC

February 2nd 2023

Mikhael and Cole Share Insights on Culturally Relevant Myeloma Care

October 27th 2022

Cilta-cel Meets PFS End Point in Relapsed/Lenalidomide-Refractory Multiple Myeloma

January 27th 2023

KRd Improves PFS as Maintenance Therapy in Transplant-Eligible Multiple Myeloma

January 25th 2023

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.